| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| OraPharma, Inc. |
| 732 Louis Drive, Warminster, PA 18974 * (215) 956-2200 |
| Business Description | The company is developing pharmaceutical products for the treatment of oral diseases and disorders. |
| Offering Information Company has | |||
| Trading As | OPHM (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 12/30/99 |
| Domestic Shares Offered | 4,000,000 | Offer Date | 3/8/00 |
| Foreign Shares Offered | 0 | Filing Range | $15.00 - $17.00 |
| Company Shares | 4,000,000 | Offer Price | $18.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.260 |
| Gross Proceeds | $72,000,000 | Selling | $0.760 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 12,600,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Gerard Klauer Mattison & Company, Incorporated | Co-manager | (212) 885-4041 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/96 | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 | ||
| Revenues | - | - | - | - | - | - | - |
| Income from Oper. | - | - | -0.435 | -2.646 | -8.915 | -4.640 | -7.245 |
| Net Income | - | - | -0.435 | -2.142 | -8.491 | -4.338 | -6.732 |
| E.P.S | - | - | - | -2.300 | -6.210 | -3.290 | -4.300 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -6.82 | -4.14 | -8.10 | ||||
| Cash Flow - Inv. | -0.70 | -0.60 | -0.17 | ||||
| Cash Flow - Fin. | 16.62 | 0.45 | 0.06 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 12.35 | Current Assets | 12.35 | Current Ratio | 20.94 |
| Total Liab. | 29.70 | Current Liab. | 0.59 | Debt Ratio | 240.55% |
| Total Equity | -17.35 | Working Cap. | 11.76 | Debt to Equity Ratio | - |
| Cash | 11.03 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for further development and commercialization of MPTS, ongoing research and development, general corporate purposes and working capital purposes, payments under licensing agreements and obtaining new product candidates or technology. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morgan, Lewis & Bockius |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Registrar/Transfer Agent | StockTrans, Inc. |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Oak Investment Partners | 21.00 | |
| Canaan Partners | 16.40 | |
| TL Ventures III | 15.70 | |
| Frazier & Company | 13.10 | |
| Domain Partners IV, L.P. | 12.30 | |
| Healthcap KB | 6.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||